
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson reported innovative medicine revenues of $15.20 billion in Q2 2025, surpassing consensus expectations, driven by strong performance in key therapeutic areas such as immunology, oncology, and neurology. The company's management also raised their FY25 sales guidance to $93.2–$93.6 billion, attributing approximately $900 million of the increase to operational growth and roughly $1.1 billion to favorable currency fluctuations, indicating robust demand and operational efficiency. Additionally, JNJ's MedTech division achieved revenues of $8.54 billion, reflecting a 4.1% year-over-year operational growth, contributing to an overall optimistic outlook for sales growth in the second half of 2025 and into 2026.
Bears say
The analysis indicates a negative outlook for Johnson & Johnson's stock primarily due to various operational pressures and uncertainties in their pharmaceutical and MedTech segments. The orthopedics and spine sales dynamics reflect challenges such as competitive headwinds and supply chain disruptions, contributing to a forecast of less than $57 billion in ex-fx revenue for 2025, compounded by lower expectations for product uptake and potential M&A integration disruptions. Additionally, the company faces risks from disappointing product launches, declining sales from key medications nearing patent expirations, and higher-than-anticipated litigation costs, which collectively undermine confidence in its growth trajectory moving forward.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares